産品名稱

産品編号

規格              

價格（元）     

Veliparib (ABT-888) 維利帕尼

MZ3701-10MG        

10mg

868

Veliparib (ABT-888) 維利帕尼         

MZ3701-50MG

50mg

2428

Veliparib (ABT-888) 維利帕尼

MZ3701-100MG

100mg

4188

         質量        

溶劑體積

濃度

1mg

5mg

10mg

1mM

4.0935 mL       

20.4675 mL       

40.9350 mL      

5mM

0.8187 mL

4.0935 mL

8.1870 mL

10mM

0.4093 mL

2.0467 mL

4.0935 mL

文獻1，Boerner JL et al. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. PLoS One. 2015 Mar 16;10(3):e0119614.PMID: 25774912

體外研究（細胞實驗）：

細胞類型（Cell type）：BRCA mutated TNBC cell lines: SUM149, SUM159 and SUM1315; HCC1937 and MDA-MB-231; MX-1;

藥物(wù)配制（Preparation）：ABT-888 was dissolved in dimethylsulphoxide (DMSO) to make a stock concentration of 10mM and stored at -20°C.

實驗方法（Assay）：Exponentially growing cells were seeded in 96-well plates (MX-1: 5,000 per well, all others: 2,000 per well) and the single agent drugs (ABT-888 or CPT-11) were addedin concentrations ranging from 0.01 nM to 100 μM the following day. When the drugs were used in combination, CPT-11 was added to media with a constant ABT-888 concentration of 500nM. Cell proliferation was determined 5 days after continuous exposure to drug by addition of MTT.

文獻2，Liu X et al.Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks. Mol Cancer Res. 2008 Oct;6(10):1621-9. PMID: 18922977

體内研究（動物(wù)模型）：

動物(wù)模型（Animal Model）：B16F10 melanoma syngeneic model

藥物(wù)配制（Preparation）：ABT-888 was delivered in a vehicle containing 0.9% NaCl adjusted to pH 4.0.

實驗方法（Assay）：B16F10 cells (6×104) were injected s.c. into the flank of female C57BL/6 mice. Mice were injection-order allocated to treatment groups, and therapy was initiated on day 1 following inoculation. ABT-888 was delivered in a vehicle containing 0.9% NaCl adjusted to pH 4.0. Temozolomide was formulated using 0.2% hydroxypropyl methylcellulose.Temozolomide was administered on an oral, qd × 5 schedule on days 6 to 10 at 50 mg/kg/d concurrently with ABT-888 on an oral, bd × 5 schedule at 25, 5, and 1 mg/kg/d.The experiment consists of 10 mice per treatment group;